Moderate TSH suppression may be better for patients with thyroid cancer
the ONA take:
According to a new study published online ahead of print in the journal Thyroid, researchers have found that moderate thyroid-stimulating hormone (TSH) suppression may be as beneficial as high suppression of the hormone responsible for driving thyroid cancer.
Higher TSH levels are associated with higher rates of thyroid cancer recurrence, but extreme suppression of TSH is linked with increased adverse events, such as arrhythmias and osteoporosis.
For the 30-year study, researchers analyzed data from 4,941 patients with thyroid cancer. Results showed that extreme TSH suppression offered no additional survival benefit compared with moderate TSH suppression in patients with high-risk disease. Moreover, researchers found that mild TSH suppression was beneficial for patients with low-risk thyroid cancer.
The findings suggest that further research is warranted to prospectively evaluate extreme TSH suppression versus moderate suppression in patients with high-risk thyroid cancer.
Moderate TSH suppression may be as beneficial as high suppression of the hormone responsible for driving the disease.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- Breast Conservation Improves Survival vs Mastectomy in Breast Cancer
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|